Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Cancer Med. 2018 Oct;7(10):5145-5154. doi: 10.1002/cam4.1763. Epub 2018 Sep 21.
Adenocarcinoma of the esophagogastric junction (AEG) has heterogeneous carcinogenic process due to its location straddling the esophagogastric junction. We assessed background mucosal pathology and its correlation with clinicopathological features of each Siewert type of AEG. Clinicopathological and immunohistochemical analyses of 103 AEGs and 58 gastric cancers (GCs) were conducted. Background mucosal features were evaluated according to the updated Sydney System. Siewert classification divided 103 AEGs into three type I, 75 type II, and 25 type III tumors, respectively. Two type I, 9 type II AEGs, and none of type III AEGs were Barrett-related and were excluded from further analysis. Background mucosa of type III AEGs more frequently showed moderate to marked degree of atrophy and intestinal metaplasia than those of type II AEGs and was very similar to those of GCs. Among type II AEGs, tumors with atrophic background were significantly associated with higher patient age and intestinal-type histology. Type II AEGs with nonatrophic background, but not those with atrophic background, showed more frequent mismatch repair deficiency, TP53 overexpression, and less frequent intestinal phenotypic markers expression than type III AEG or GC. Type II AEGs with atrophic background involved suprapancreatic nodes more frequently than those without. We demonstrated that chronic atrophic gastritis was a major precancerous condition of AEG in the Japanese population, especially Siewert type III which had background mucosal pathology similar to that of GC. Type II AEGs with and without atrophic background showed some clinicopathological differences, and these observations might represent heterogeneous carcinogenic process within type II AEGs.
胃食管结合部腺癌(AEG)由于其位置跨越食管胃结合部,具有异质性的致癌过程。我们评估了背景黏膜病理学及其与各型 Siewert 食管胃结合部腺癌的临床病理特征的相关性。对 103 例 AEG 和 58 例胃癌(GC)进行了临床病理和免疫组织化学分析。根据更新的悉尼系统评估背景黏膜特征。Siewert 分类将 103 例 AEG 分为 3 型 I、75 型 II 和 25 型 III 肿瘤。2 型 I、9 型 II AEG 和 3 型 III AEG 均无 Barrett 相关性,因此被排除在进一步分析之外。与 II 型 AEG 和 GC 相比,III 型 AEG 的背景黏膜更频繁地表现出中度至明显的萎缩和肠化生。在 II 型 AEG 中,萎缩背景下的肿瘤与较高的患者年龄和肠型组织学显著相关。非萎缩背景下的 II 型 AEG 与 III 型 AEG 或 GC 相比,更频繁地表现出错配修复缺陷、TP53 过表达和较少的肠表型标志物表达,但不包括萎缩背景下的 II 型 AEG。非萎缩背景下的 II 型 AEG 比无萎缩背景下的 II 型 AEG 更频繁地累及胰上淋巴结。我们表明,慢性萎缩性胃炎是日本人群 AEG 的主要癌前病变,尤其是 Siewert 型 III,其背景黏膜病理学与 GC 相似。有和无萎缩背景的 II 型 AEG 表现出一些临床病理差异,这些观察结果可能代表 II 型 AEG 内异质性的致癌过程。